Stock Screener App

Frei -

Installieren

63.63

0.89% -0.57

Cytokinetics Inc (CYTK)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt CYTK? Forum Prognose Aktiensplit

Cytokinetics Inc Aktie (CYTK) Neueste Nachrichten

Cytokinetics at Barclays Conference: Strategic Growth and Global Ambitions - Investing.com

Cytokinetics, Incorporated (CYTK) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire

Leerink Maintains Outperform for Cytokinetics, Incorporated (CYTK) March 2026 - Meyka

Robert Blum Sells 7,931 Shares of Cytokinetics (NASDAQ:CYTK) Stock - MarketBeat

Cytokinetics (NASDAQ:CYTK) EVP Sells $156,779.04 in Stock - MarketBeat

Cytokinetics Leaders Gained $16 Million as Insiders, Suit Says - Bloomberg Law News

Cytokinetics at The Citizens Life Sciences Conference: Myqorzo’s Market Potential - Investing.com Canada

Leerink reiterates Cytokinetics stock rating on launch confidence By Investing.com - Investing.com Canada

Cytokinetics Insider Exercises Options Worth Over $920,000 as Heart Drug Hits the Market - Yahoo Finance

Cytokinetics Insider Exercises Options Worth Over $920,000 as Heart Drug Hits the Market - The Motley Fool

Cytokinetics at Leerink Global Healthcare Conference: Strategic Growth in Cardiology - Investing.com Canada

UBS Maintains Neutral on CYTK, Cytokinetics, Incorporated March 2026 - Meyka

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Cytokinetics, Incorporated (CYTK) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire

Leerink Partners Global Biopharma Conference 2026: TEVA, CYTK, IMRX, TNYA And More Set To Present - RTTNews

Rhenman & Partners Asset Management AB Raises Stake in Cytokinetics, Incorporated $CYTK - MarketBeat

Knott David M Jr Purchases Shares of 30,000 Cytokinetics, Incorporated $CYTK - MarketBeat

GW&K Investment Management LLC Takes $9.93 Million Position in Cytokinetics, Incorporated $CYTK - MarketBeat

GABELLI & Co INVESTMENT ADVISERS INC. Makes New $2.06 Million Investment in Cytokinetics, Incorporated $CYTK - MarketBeat

Cytokinetics (CYTK) Analyst Rating: UBS Raises Price Target to $69.00 | CYTK Stock News - GuruFocus

Analysts Offer Insights on Healthcare Companies: Cytokinetics (CYTK), Ascendis Pharma (ASND) and Avalo Therapeutics (AVTX) - The Globe and Mail

Callos, Cytokinetics EVP, sells $1.6 million in CYTK stock - Investing.com UK

Callos, Cytokinetics EVP, sells $1.6 million in CYTK stock By Investing.com - Investing.com South Africa

Cytokinetics: From Aficamten Trials to MYQORZO Launch—A High-Stakes Race in the HCM Market! - Smartkarma

Cytokinetics (NASDAQ:CYTK) EVP Andrew Callos Sells 26,000 Shares - MarketBeat

Bronstein, Gewirtz & Grossman, LLC Encourages Cytokinetics, Incorporated (CYTK) Investors to Inquire about Securities Investigation - ACCESS Newswire

Segall Bryant & Hamill LLC Boosts Position in Cytokinetics, Incorporated $CYTK - MarketBeat

Royce & Associates LP Invests $5.50 Million in Cytokinetics, Incorporated $CYTK - MarketBeat

Legato Capital Management LLC Takes Position in Cytokinetics, Incorporated $CYTK - MarketBeat

Fisher Asset Management LLC Raises Stock Holdings in Cytokinetics, Incorporated $CYTK - MarketBeat

Cytokinetics Is Priced For A Big MYQORZO Launch - Finimize

Rafferty Asset Management LLC Has $5.72 Million Holdings in Cytokinetics, Incorporated $CYTK - MarketBeat

CYTK Should I Buy - Intellectia AI

Cytokinetics, Incorporated (NASDAQ:CYTK) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat

Cytokinetics Wins Dual MYQORZO Approvals But Faces Execution And Loss Risks - simplywall.st

Insider Sell: B Parshall Sells 5,000 Shares of Cytokinetics Inc (CYTK) - GuruFocus

EVP at Cytokinetics (NASDAQ: CYTK) sells 886 shares after option exercise - Stock Titan

[144] CYTOKINETICS INC SEC Filing - Stock Titan

Director Lynne Parshall trims Cytokinetics (CYTK) stake in sale - Stock Titan

Cytokinetics to Participate in March Investor Conferences - The Manila Times

March investor fireside chats: Cytokinetics to webcast - Stock Titan

Cytokinetics, Incorporated (CYTK) Stock Analysis: A Biotech With A 46.52% Potential Upside - DirectorsTalk Interviews

Cytokinetics, Incorporated $CYTK Stock Position Raised by Handelsbanken Fonder AB - MarketBeat

CYTK Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan

Assessing Cytokinetics (CYTK) Valuation After Recent Share Price Weakness And Aficamten Expectations - Yahoo Finance

A Look At Cytokinetics (CYTK) Valuation After Recent Share Price Pullback - simplywall.st

Monashee Investment Management LLC Buys Shares of 100,000 Cytokinetics, Incorporated $CYTK - MarketBeat

Cytokinetics (HAM:KK3A) Total Receivables : €1.54 Mil (As of Sep. 2025) - GuruFocus

Cytokinetics (HAM:KK3A) Inventories, Raw Materials & Components : €0.00 Mil (As of Sep. 2025) - GuruFocus

TD Asset Management Inc Raises Stake in Cytokinetics, Incorporated $CYTK - MarketBeat

Cytokinetics (HAM:KK3A) Inventories, Inventories Adjustments : €0.00 Mil (As of Sep. 2025) - GuruFocus

Cytokinetics (HAM:KK3A) YoY Rev. per Sh. Growth : 250.00% (As of Sep. 2025) - GuruFocus

Cytokinetics (HAM:KK3A) FCF Margin % : -6,037.84% (As of Sep. 2025) - GuruFocus

Cytokinetics (HAM:KK3A) Total Equity : €-444.00 Mil (As of Sep. 2025) - GuruFocus

Cytokinetics (HAM:KK3A) Research & Development : €0.00 Mil (TTM As of Sep. 2025) - GuruFocus

HC Wainwright Estimates Cytokinetics Q3 Earnings - MarketBeat

Cytokinetics (HAM:KK3A) 1-Year ROIIC % : -84.62% (As of Sep. 2025) - GuruFocus

Cytokinetics (HAM:KK3A) Investments And Advances : €246.07 Mil (As of Sep. 2025) - GuruFocus

Cytokinetics (HAM:KK3A) COGS-to-Revenue : 51.27 (As of Sep. 2025) - GuruFocus

Cytokinetics (HAM:KK3A) Land And Improvements : €0.00 Mil (As of Sep. 2025) - GuruFocus

Cytokinetics (HAM:KK3A) Operating Cash Flow per Share : €-3.25 (TTM As of Sep. 2025) - GuruFocus

Cytokinetics (HAM:KK3A) Debt-to-Asset : 0.83 (As of Sep. 2025) - GuruFocus

Decoding Cytokinetics Inc (CYTK): A Strategic SWOT Insight - GuruFocus

Cytokinetics (HAM:KK3A) Debt-to-EBITDA : -1.08 (As of Sep. 2025) - GuruFocus

Cytokinetics (HAM:KK3A) EBITDA Margin % : -14,321.10% (As of Sep. 2025) - GuruFocus

Cytokinetics (HAM:KK3A) Change In Prepaid Assets : €-7.08 Mil (TTM As of Sep. 2025) - GuruFocus

Cytokinetics (HAM:KK3A) 3-Year RORE % : 2.84% (As of Sep. 2025) - GuruFocus

Cytokinetics (CYTK) pivots to commercial growth with MYQORZO and heart failure pipeline - Stock Titan

RPRX

$46.69

1.57%

ROIV

$29.58

0.40%

MRNA

$55.97

1.80%

BNTX

$90.84

8.28%

INSM

$139.40

3.09%

ONC

$298.91

2.12%

In Yahoo öffnen | In Google öffnen | In Finviz öffnen | In MarketWatch öffnen | Öffnen Sie in EDGAR | Offen in Reuters